IMMUNOGEN

ImmunoGen, Inc. Investor Relations Department 830 Winter Street Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐


NASDAQ: IMGN	
Last Trade:	7.00
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	0.46 🕇 (+7.034%)
Day Range	6.45 - 7.10
52-Week Range	1.51 - 7.00
Volume	4,097,439

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinicalstage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate. mirvetuximab soravtansine, is in a Phase 3 trial for FRαpositive platinumresistant ovarian cancer. and is in Phase 1b/2 testing in combination regimens for earlierstage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla[®], in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX... (more)

Stock Performance



Press Releases [View all]

Jun 26, 2017

ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia

May 30, 2017

ImmunoGen and Sanofi Amend License Agreements

May 24, 2017

ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference

May 23, 2017

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

May 17, 2017

ImmunoGen Announces New Clinical Data
with Mirvetuximab Soravtansine in Ovarian
Cancer to be Presented at 2017 ASCO
Annual Meeting

Financials [View all]

First Quarter Financial Results

Aug 25, 2016

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)

May 4, 2016

Quarterly Report (10-Q)